NASDAQ$STRO
Sutro Biopharma Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Sutro Biopharma reported financial results for the third quarter of 2021, highlighted business updates, and previewed anticipated milestones for the remainder of 2021.
Sutro Biopharma reported revenue of $8.5 million for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $254.2 million as of September 30, 2021, projecting a cash runway into the second half of 2023.
- Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, with an interim data update expected in the second half of 2021.
- STRO-001 Phase 1 dose escalation for non-Hodgkin’s lymphoma and multiple myeloma is ongoing to achieve a recommended Phase 2 dose.
- Cash, cash equivalents and marketable securities totaled $254.2 million as of September 30, 2021, with projected cash runway into the second half of 2023.
- Merck has extended the first cytokine derivative research program by up to two years.
Headline financials
Revenue & EPS history
Sutro · Revenue · Quarterly
$8.52M
Revenue by segment
Sutro · $14.5M total across 2 segments · Q1 2026
- Astellas Pharma Inc.$14.5M—99.9%
- Vaxcyte, Inc.$15K—0.1%
Forward guidance
Sutro Biopharma is advancing its pipeline, including STRO-002 and STRO-001, and expects to report initial data for the STRO-002 dose-expansion cohort in the second half of 2021.
Tailwinds
- STRO-002 patient enrollment completed for ovarian cancer dose-expansion cohort.
- STRO-002 study in combination with bevacizumab has cleared protocol, with the first patient expected later this year.
- STRO-001 dose escalation is ongoing to achieve a recommended phase 2 dose.
- Sutro entered into a collaboration with BioNova Pharmaceuticals Limited to assess the therapeutic potential for STRO-001.
- Merck extended the first cytokine derivative research program by up to two years.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2021
-0.8%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+3.4%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+22.2%
Q4 2023
Best reaction
-29.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.8% | -1.6% | — | |
| Q1 2026 | -3.1% | -20.2% | -27.0% | |
| Q3 2025 | -15.8% | -13.8% | -7.9% | |
| Q2 2025 | -2.1% | -4.9% | +29.3% | |
| Q1 2025 | -3.8% | -1.1% | -3.3% | |
| Q4 2024 | -11.7% | -20.3% | +21.6% | |
| Q3 2024 | -15.4% | -32.6% | -48.0% | |
| Q2 2024 | +10.8% | +29.9% | +37.3% | |
| Q1 2024 | +4.6% | -3.4% | -6.0% | |
| Q4 2023 | +22.2% | +65.2% | +1.5% | |
| Q3 2023 | +13.9% | +29.3% | +88.9% | |
| Q2 2023 | +0.9% | +1.2% | +7.1% | |
| Q1 2023 | +1.6% | -4.1% | -5.3% | |
| Q4 2022 | -3.1% | -9.6% | -10.7% | |
| Q3 2022 | -2.5% | -3.7% | +4.6% | |
| Q2 2022 | +14.6% | +23.1% | -2.4% | |
| Q1 2022 | -6.8% | -19.6% | -19.2% | |
| Q4 2021 | -2.5% | -8.0% | -8.3% | |
| Q3 2021 | -5.3% | -11.3% | -32.2% | |
| Q2 2021 | -0.2% | +2.3% | +12.4% | |
| Q1 2021 | +8.3% | +9.7% | -0.5% | |
| Q4 2020 | +4.2% | -3.7% | -16.5% | |
| Q3 2020 | +17.8% | +12.4% | +62.7% | |
| Q2 2020 | +1.7% | +1.0% | +48.9% | |
| Q1 2020 | -9.8% | -8.1% | +0.4% | |
| Q4 2019 | -29.4% | -19.9% | -3.4% | |
| Q3 2019 | -1.1% | -1.2% | -7.5% | |
| Q2 2019 | -7.0% | -3.8% | +19.6% | |
| Q1 2019 | -7.6% | -7.9% | +1.8% | |
| Q4 2018 | +5.4% | -1.2% | -12.6% | |
| Q3 2018 | -5.0% | -13.1% | -23.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro